129 research outputs found
Associations between multimorbidity and neuropathology in dementia: Consideration of functional cognitive disorders, psychiatric illness and dementia mimics
\ua9 The Author(s), 2024. Published by Cambridge University Press on behalf of Royal College of Psychiatrists.Background Multimorbidity, the presence of two or more health conditions, has been identified as a possible risk factor for clinical dementia. It is unclear whether this is due to worsening brain health and underlying neuropathology, or other factors. In some cases, conditions may reflect the same disease process as dementia (e.g. Parkinson\u27s disease, vascular disease), in others, conditions may reflect a prodromal stage of dementia (e.g. depression, anxiety and psychosis). Aims To assess whether multimorbidity in later life was associated with more severe dementia-related neuropathology at autopsy. Method We examined ante-mortem and autopsy data from 767 brain tissue donors from the UK, identifying physical multimorbidity in later life and specific brain-related conditions. We assessed associations between these purported risk factors and dementia-related neuropathological changes at autopsy (Alzheimer\u27s-disease related neuropathology, Lewy body pathology, cerebrovascular disease and limbic-predominant age-related TDP-43 encephalopathy) with logistic models. Results Physical multimorbidity was not associated with greater dementia-related neuropathological changes. In the presence of physical multimorbidity, clinical dementia was less likely to be associated with Alzheimer\u27s disease pathology. Conversely, conditions which may be clinical or prodromal manifestations of dementia-related neuropathology (Parkinson\u27s disease, cerebrovascular disease, depression and other psychiatric conditions) were associated with dementia and neuropathological changes. Conclusions Physical multimorbidity alone is not associated with greater dementia-related neuropathological change; inappropriate inclusion of brain-related conditions in multimorbidity measures and misdiagnosis of neurodegenerative dementia may better explain increased rates of clinical dementia in multimorbidit
Plasma metabolites distinguish dementia with Lewy bodies from Alzheimer’s disease: a cross-sectional metabolomic analysis
Copyright \ua9 2024 Pan, Donaghy, Roberts, Chouliaras, O’Brien, Thomas, Heslegrave, Zetterberg, McGuinness, Passmore, Green and Kane.Background: In multifactorial diseases, alterations in the concentration of metabolites can identify novel pathological mechanisms at the intersection between genetic and environmental influences. This study aimed to profile the plasma metabolome of patients with dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD), two neurodegenerative disorders for which our understanding of the pathophysiology is incomplete. In the clinical setting, DLB is often mistaken for AD, highlighting a need for accurate diagnostic biomarkers. We therefore also aimed to determine the overlapping and differentiating metabolite patterns associated with each and establish whether identification of these patterns could be leveraged as biomarkers to support clinical diagnosis. Methods: A panel of 630 metabolites (Biocrates MxP Quant 500) and a further 232 metabolism indicators (biologically informative sums and ratios calculated from measured metabolites, each indicative for a specific pathway or synthesis; MetaboINDICATOR) were analyzed in plasma from patients with probable DLB (n = 15; age 77.6 \ub1 8.2 years), probable AD (n = 15; 76.1 \ub1 6.4 years), and age-matched cognitively healthy controls (HC; n = 15; 75.2 \ub1 6.9 years). Metabolites were quantified using a reversed-phase ultra-performance liquid chromatography column and triple-quadrupole mass spectrometer in multiple reaction monitoring (MRM) mode, or by using flow injection analysis in MRM mode. Data underwent multivariate (PCA analysis), univariate and receiving operator characteristic (ROC) analysis. Metabolite data were also correlated (Spearman r) with the collected clinical neuroimaging and protein biomarker data. Results: The PCA plot separated DLB, AD and HC groups (R2 = 0.518, Q2 = 0.348). Significant alterations in 17 detected metabolite parameters were identified (q ≤ 0.05), including neurotransmitters, amino acids and glycerophospholipids. Glutamine (Glu; q = 0.045) concentrations and indicators of sphingomyelin hydroxylation (q = 0.039) distinguished AD and DLB, and these significantly correlated with semi-quantitative measurement of cardiac sympathetic denervation. The most promising biomarker differentiating AD from DLB was Glu:lysophosphatidylcholine (lysoPC a 24:0) ratio (AUC = 0.92; 95%CI 0.809–0.996; sensitivity = 0.90; specificity = 0.90). Discussion: Several plasma metabolomic aberrations are shared by both DLB and AD, but a rise in plasma glutamine was specific to DLB. When measured against plasma lysoPC a C24:0, glutamine could differentiate DLB from AD, and the reproducibility of this biomarker should be investigated in larger cohorts
Sustained attention in mild cognitive impairment with Lewy bodies and Alzheimer\u27s disease
\ua9 The Author(s), 2023. Published by Cambridge University Press on behalf of International Neuropsychological Society. Objective: Attentional impairments are common in dementia with Lewy bodies and its prodromal stage of mild cognitive impairment (MCI) with Lewy bodies (MCI-LB). People with MCI may be capable of compensating for subtle attentional deficits in most circumstances, and so these may present as occasional lapses of attention. We aimed to assess the utility of a continuous performance task (CPT), which requires sustained attention for several minutes, for measuring attentional performance in MCI-LB in comparison to Alzheimer\u27s disease (MCI-AD), and any performance deficits which emerged with sustained effort. Method: We included longitudinal data on a CPT sustained attention task for 89 participants with MCI-LB or MCI-AD and 31 healthy controls, estimating ex-Gaussian response time parameters, omission and commission errors. Performance trajectories were estimated both cross-sectionally (intra-task progress from start to end) and longitudinally (change in performance over years). Results: While response times in successful trials were broadly similar, with slight slowing associated with clinical parkinsonism, those with MCI-LB made considerably more errors. Omission errors were more common throughout the task in MCI-LB than MCI-AD (OR 2.3, 95% CI: 1.1-4.7), while commission errors became more common after several minutes of sustained attention. Within MCI-LB, omission errors were more common in those with clinical parkinsonism (OR 1.9, 95% CI: 1.3-2.9) or cognitive fluctuations (OR 4.3, 95% CI: 2.2-8.8). Conclusions: Sustained attention deficits in MCI-LB may emerge in the form of attentional lapses leading to omissions, and a breakdown in inhibitory control leading to commission errors
Mild cognitive impairment with Lewy bodies: neuropsychiatric supportive symptoms and cognitive profile
This is the author accepted manuscript. The final version is available from Cambridge University Press via the DOI in this recordBackground
Recently published diagnostic criteria for mild cognitive impairment with Lewy bodies (MCI-LB)
include five neuropsychiatric supportive features (non-visual hallucinations, systematised delusions,
apathy, anxiety and depression). We have previously demonstrated that the presence of two or
more of these symptoms differentiates MCI-LB from MCI due to Alzheimer’s disease (MCI-AD) with a
likelihood ratio >4. The aim of this study was to replicate the findings in an independent cohort.
Methods
Participants ≥60 years old with MCI were recruited. Each participant had a detailed clinical, cognitive
and imaging assessment including FP-CIT SPECT and cardiac MIBG. The presence of neuropsychiatric
supportive symptoms was determined using the neuropsychiatric inventory (NPI). Participants were
classified as MCI-AD, possible MCI-LB and probable MCI-LB based on current diagnostic criteria.
Participants with possible MCI-LB were excluded from further analysis.
Results
Probable MCI-LB (n=28) had higher NPI total and distress scores than MCI-AD (n=30). 59% of MCI-LB
had two or more neuropsychiatric supportive symptoms compared with 9% of MCI-AD (likelihood
ratio 6.5, p<0.001). MCI-LB participants also had significantly greater delayed recall and a lower
Trails A:Trails B ratio than MCI-AD.
Conclusions
5
MCI-LB is associated with significantly greater neuropsychiatric symptoms than MCI-AD. The
presence of two or more neuropsychiatric supportive symptoms as defined by MCI-LB diagnostic
criteria is highly specific and moderately sensitive for a diagnosis of MCI-LB. The cognitive profile of
MCI-LB differs from MCI-AD, with greater executive and lesser memory impairment, but these
differences are not sufficient to differentiate MCI-LB from MCI-AD.Alzheimer’s Research UKNational Institute for Health Research (NIHR
Olfactory impairment in mild cognitive impairment with Lewy bodies and Alzheimer’s disease
This is the author accepted manuscript. The final version is available from Cambridge University Press via the DOI in this recordObjectives:
Impaired olfaction may be a biomarker for early Lewy body disease but its value in Mild
Cognitive Impairment with Lewy bodies (MCI-LB) is unknown. We compared olfaction in
MCI-LB with MCI due to Alzheimer’s disease (MCI-AD) and healthy older adults. We
hypothesised that olfactory function would be worse in probable MCI-LB than in both MCI-
AD and healthy comparison subjects (HC).
Design:
Cross-sectional study assessing olfaction using Sniffin’ Sticks 16 (SS-16) in MCI-LB, MCI-
AD and HC with longitudinal follow-up. Differences were adjusted for age and receiver
operating characteristic curves were used for discriminating MCI-LB from MCI-AD andHC.
Setting:
Participants were recruited from Memory Services in the North East of England
Participants:
38 probable MCI-LB, 33 MCI-AD, 19 possible MCI-LB and 32HC.
Measurements:
Olfaction was assessed using SS-16 and a questionnaire.
Results:
Participants with probable MCI-LB had worse olfaction than both MCI-AD (Age-adjusted
mean difference (B)=2.05,95% CI:0.62-3.49, p=.005) and HC (B=3.96, 95% CI:2.51–5.40,
p<.001). The previously-identified cut-off score for the SS-16 of ≤ 10 had 84% sensitivity for
probable MCI-LB (95% CI: 69-94%) but 30% specificity vs MCI-AD. ROC analysis found a
lower cut-off of ≤ 7 was better (63% sensitivity for MCI-LB, with 73% specificity vs MCI-AD
and 97% vsHC). Asking about olfactory impairments was not useful in identifying them.
Conclusions:
MCI-LB had worse olfaction than MCI-AD and normal ageing. A lower cut-off score of ≤ 7 is
required when using SS-16 in such patients. Olfactory testing may have value in identifying
early LB disease in memory services.Alzheimer’s Research UKNational Institute for Health Research (NIHR
Mild cognitive impairment with Lewy bodies: blood perfusion with arterial spin labelling
This is the final version. Available on open access from via the DOI in this recordObjective: To use arterial spin labelling (ASL) to investigate differences in perfusion in mild cognitive
impairment with Lewy bodies (MCI-LB) compared to Alzheimer type MCI (MCI-AD) and healthy
controls.
Methods: We obtained perfusion images on 32 MCI-LB, 30 MCI-AD and 28 healthy subjects of similar
age. Perfusion relative to cerebellum was calculated, and we aimed to examine differences in
relative perfusion between MCI-LB and the other groups. This included whole brain voxelwise
comparisons, as well as using predefined region-of-interest ratios of medial occipital to medial
temporal, and posterior cingulate to precuneus. Differences in occipital perfusion in eyes open vs
eyes closed conditions were also examined.
Results: Compared to controls, the MCI-LB showed reduced perfusion in the precuneus, parietal,
occipital and fusiform gyrus regions. In our predefined regions, the ratio of perfusion in occipital /
medial temporal was significantly lower, and the posterior cingulate / precuneus ratio significantly
higher in MCI-LB compared to controls. Overall, the occipital perfusion was greater in the eyes open
vs closed condition, but this did not differ between groups.
Conclusion: We found patterns of altered perfusion in MCI-LB which are similar to those seen in
dementia with Lewy bodies, with reduction in posterior parietal and occipital regions, but relatively
preserved posterior cingulate.Alzheimer’s Research UKNational Institute for Health Research (NIHR
Long-term impact of the COVID-19 pandemic on the quality of life of people with dementia and their family carers
\ua9 The Author(s) 2024. Published by Oxford University Press on behalf of the British Geriatrics Society. INTRODUCTION: Few studies have longitudinally mapped quality of life (QoL) trajectories of newly diagnosed people with dementia and their carers, particularly during coronavirus disease-2019 (COVID-19). METHODS: In a UK cohort study, 261 newly diagnosed people with dementia and 206 family carers were assessed prior to the pandemic (July 2019-March 2020), followed up after the first lockdown (July-October 2020) and then again a year and 2 years later. Latent growth curve modelling examined the level and change of QoL over the four time-points using dementia-specific QoL measures (DEMQOL and C-DEMQOL). RESULTS: Despite variations in individual change scores, our results suggest that generally people with dementia maintained their QoL during the pandemic and experienced some increase towards the end of the period. This contrasted with carers who reported a general deterioration in their QoL over the same period. \u27Confidence in future\u27 and \u27Feeling supported\u27 were the only carer QoL subscales to show some recovery post-pandemic. DISCUSSION: It is positive that even during a period of global disruption, decline in QoL is not inevitable following the onset of dementia. However, it is of concern that carer QoL declined during this same period even after COVID-19 restrictions had been lifted. Carers play an invaluable role in the lives of people with dementia and wider society, and our findings suggest that, post-pandemic, they may require greater support to maintain their QoL
In Situ Distribution of HIV-Binding CCR5 and C-Type Lectin Receptors in the Human Endocervical Mucosa
The endocervical mucosa is believed to be a primary site of HIV transmission. However, to date there is little known about the distribution of the HIV co-receptor CCR5 and the HIV-binding C-type lectin receptors, including Langerin, dendritic cell (DC)-specific intercellular adhesion molecule-grabbing non-integrin (DC-SIGN) and mannose receptor (MR) at this site. We therefore characterized the expression of these molecules in the endocervix of HIV seronegative women by computerized image analysis. Endocervical tissue biopsies were collected from women (n = 6) undergoing hysterectomy. All study individuals were diagnosed with benign and non-inflammatory diseases. CCR5+ CD4+ CD3+ T cells were found within or adjacent to the endocervical epithelium. The C-type lectin Langerin was expressed by intraepithelial CD1a+ CD4+ and CD11c+ CD4+ Langerhans cells, whereas DC-SIGN+ MR+ CD11c myeloid dendritic cells and MR+ CD68+ macrophages were localized in the submucosa of the endocervix. The previously defined immune effector cells including CD8+, CD56+, CD19+ and IgD+ cells were also found in the submucosa as well as occasional CD123+ BDCA-2+ plasmacytoid dendritic cells. Understanding the spatial distribution of potential HIV target cells and immune effector cells in relation to the endocervical canal forms a basis for deciphering the routes of HIV transmission events in humans as well as designing HIV-inhibiting compounds
- …